Concurrent sulforaphane and eugenol induces differential effects on human cervical cancer cells

Integrative Cancer Therapies

Volumn 11, Issue 2, 2012, Pages 154-165

  Hussain, Arif ^a   Priyani, Anita ^a   Sadrieh, Lida ^a   Brahmbhatt, Kruti ^a   Ahmed, Musthaq ^a   Sharma, Chhavi ^a  

^a Dubai International Academic City   (United Arab Emirates)

Author keywords

antagonistic; Bcl 2; chemoprevention; combination; COX 2; eugenol; gemcitabine; IL 1 ; sulforaphane; synergistic

Indexed keywords

CYCLOOXYGENASE 2; EUGENOL; GEMCITABINE; INTERLEUKIN 1BETA; PROTEIN BCL 2; SULFORAPHANE;

APOPTOSIS; ARTICLE; CALCULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2; DEOXYCYTIDINE; DOWN-REGULATION; DRUG SYNERGISM; EUGENOL; FEMALE; HELA CELLS; HUMANS; INTERLEUKIN-1BETA; PROTO-ONCOGENE PROTEINS C-BCL-2; THIOCYANATES; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84862024274     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735411400313     Document Type: Article

References (87)

1. Li Y, Ellis KL, Ali S, et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas. 2004;28:90-95.
2. Scott EN, Gescher AJ, Steward WP, Brown K. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila). 2009;2:525-530.
3. Szumiło J. Natural compounds in chemoprevention of esophageal squamous cell tumors - experimental studies [in Polish]. Pol Merkur Lekarski. 2009;26:156-161.
4. Kelloff GJ, Crowell JA, Steele VE, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr. 2000;130(2S suppl): S467-S471.
5. Saba N, Khuri F. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Oncology. 2005;68:18-22. (Pubitemid 40675004)
6. Syed DN, Suh Y, Afaq F, Mukhtar H. Dietary agents for chemoprevention of prostate cancer. Cancer Lett. 2008;265:167-176.
7. Thangapazham RL, Sharma A, Maheshwari RK. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J. 2006;8:E443-E449. (Pubitemid 44096605)
8. Reddy BS. Strategies for colon cancer prevention: combination of chemopreventive agents. Subcell Biochem. 2007;42:213-225.
9. Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 2003;63:4158-4166. (Pubitemid 36917941)
10. Lev-Ari S, Vexler A, Starr A, et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest. 2007;25:411-418. (Pubitemid 47450667)
11. Park J, Ayyappan V, Bae EK, et al. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol. 2008;2:317-326.
12. Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82: 1013-1016. (Pubitemid 30128852)
13. Azzoli CG, Miller VA, Ng KK, et al. Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am J Clin Oncol. 2003;26:247-251. (Pubitemid 36712636)
14. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett. 2004;215:129-140. (Pubitemid 39370030)
15. de Kok TM, van Breda SG, Manson MM. Mechanisms of combined action of different chemopreventive dietary compounds: a review. Eur J Nutr. 2008;47:51-59. (Pubitemid 351644180)
16. Milner JA, McDonald SS, Anderson DE, Greenwald P. Molecular targets for nutrients involved with cancer prevention. Nutr Cancer. 2001;41:1-16. (Pubitemid 34666215)
17. Ip C, Ganther HE. Combination of blocking agents and suppressing agents in cancer prevention. Carcinogenesis. 1991;12:365-367.
18. Kowalczyk MC, Walaszek Z, Kowalczyk P, Kinjo T, Hanausek M, Slaga TJ. Differential effects of several phytochemicals and their derivatives on murine keratinocytes in vitro and in vivo: implications for skin cancer prevention. Carcinogenesis. 2009;30:1008-1015.
19. Nakamura Y, Yogosawa S, Izutani Y, Watanabe H, Otsuji E, Sakai T. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer. 2009;8:100.
20. Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG. Quantitation of chemopreventive synergism between (-)- epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis. 1998;19:419-424. (Pubitemid 28375443)
21. Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin. 2007;28:1343-1354. (Pubitemid 47366676)
22. Myzak MC, Dashwood RH. Chemoprotection by sulforaphane: keep one eye beyond keap1. Cancer Lett. 2006;233:208-218. (Pubitemid 43327375)
23. Ogata M, Hoshi M, Urano S, Endo T. Antioxidant activity of eugenol and related monomeric and dimeric compounds. Chem Pharm Bull (Tokyo). 2000;48:1467-1469.
24. Ghosh R, Nadiminty N, Fitzpatrick JE, Alworth WL, Slaga TJ, Kumar AP. Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. J Biol Chem. 2005;280:5812-5819. (Pubitemid 40280062)
25. Yoo CB, Han KT, Cho KS, et al. Eugenol isolated from the essential oil of Eugenia caryophyllata induces a reactive oxygen species mediated apoptosis in HL-60 human promyelocytic leukemia cells. Cancer Lett. 2005;225: 41-52.
26. Dash PR, Cartwright JE, Whitley GS. Nitric oxide inhibits polyamine-induced apoptosis in the human extravillous trophoblast cell line SGHPL-4. Hum Reprod. 2003;18:959-968. (Pubitemid 36592035)
27. Sharma C, Kaur J, Shishodia S, Aggarwal BB, Ralhan R. Curcumin downregulates smokeless tobacco-induced NF-κB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology. 2006;228: 1-15. (Pubitemid 44548099)
28. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
29. Sharma R, Chattopadhyay TK, Mathur M, Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology. 2004;67:300-309. (Pubitemid 39551715)
30. Wang AG, Kim SU, Lee SH, et al. Histone deacetylase 1 contributes to cell cycle and apoptosis. Biol Pharm Bull. 2005;28:1966-1970. (Pubitemid 41437091)
31. Bondesen BA, Mills ST, Kegley KM, Pavlath GK. The COX-2 pathway is essential during early stages of skeletal muscle regeneration. Am J Physiol Cell Physiol. 2004;287:C475-C483. (Pubitemid 38955239)
32. Salemi S, Rethage J, Wollina U, et al. Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol. 2003;30:146-150. (Pubitemid 36077786)
33. Sharma C, Ahmed T, Sasidharan S, Ahmed M, Hussain A. Use of gemcitabine and ginger extract infusion may improve the efficiency of cervical cancer treatment. Afr J Biotechnol. 2009;8:7087-7093.
34. Morris JA, Zhang D, Coleman KG, Nagle J, Pentchev PG, Carstea ED. The genomic organization and polymorphism analysis of the human Niemann-Pick C1 gene. Biochem Biophys Res Commun. 1999;261:493-498. (Pubitemid 29392504)
35. Candelaria M, Garcia-Arias A, Cetina L, Dueñas-Gonzalez A. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol. 2006;1:15.
36. Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003;68:217-226. (Pubitemid 38373421)
37. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;1397-1421.
38. Surh YJ, Na HK. NF-κB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with antiinflammatory and antioxidant phytochemicals. Genes Nutr. 2008;2:313-317.
39. Davidson PG, Touger-Decker R. Chemopreventive role of fruits and vegetables in oropharyngeal cancer. Nutr Clin Pract. 2009;24:250-260.
40. Liu RH. potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr. 2004;134:3479-3485.
41. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-1155. (Pubitemid 26137973)
42. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786. (Pubitemid 26091640)
43. Waladkhani AR, Clemens MR. Effect of dietary phytochemicals on cancer development. Int J Mol Med. 1998;1:747-753.
44. Liu RH. Whole grain phytochemicals and health. J Cereal Sci. 2007;46:207-219. (Pubitemid 47633134)
45. Pappa G, Strathmann J, Löwinger M, Bartsch H, Gerhäuser C. Quantitative combination effects between sulforaphane and 3,3′- diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis. 2007;28:1471-1477. (Pubitemid 47241796)
46. Cheah YH, Nordin FJ, Sarip R, et al. Combined xanthorrhizolcurcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231. Cancer Cell Int. 2009;9:1.
47. Bonnesen C, Eggleston IM, Hayes JD. Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res. 2001;61:6120-6130. (Pubitemid 32762548)
48. Gerhäuser C, You M, Liu J, et al. Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer Res. 1997;57:272-278. (Pubitemid 27036605)
49. Brooks JD, Paton VG, Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev. 2001;10:949-954. (Pubitemid 32844902)
50. Sun J, Chu YF, Wu X, Liu RH. Antioxidant and antiproliferative activities of common fruits. Agric Food Chem. 2002;50:7449-7454. (Pubitemid 35424917)
51. van Breda SG, van Agen E, van Sanden S, Burzykowski T, Kleinjans JC, Delft JH. Vegetables affect the expression of genes involved in carcinogenic and anticarcinogenic processes in the lungs of female C57BL/6 mice. J Nutr. 2005;135:2546-2552. (Pubitemid 43158409)
52. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006;66:3347-3350.
53. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764. (Pubitemid 26185452)
54. Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005;65:9064-9072. (Pubitemid 41377399)
55. Gamet-Payrastre L, Li P, Lumeau S, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000;60:1426-1433. (Pubitemid 30152017)
56. Fujisawa S, Atsumi T, Kadoma Y, Sakagami H. Antioxidant and prooxidant action of eugenol-related compounds and their cytotoxicity. Toxicology. 2002;177:39-54. (Pubitemid 34786243)
57. Banerjee S, Das S. Anticarcinogenic effects of an aqueous infusion of cloves on skin carcinogenesis. Asian Pac J Cancer Prev. 2005;6:304-308.
58. Okada N, Hirata A, Murakami Y, Shoji M, Sakagami H, Fujisawa S. Induction of cytotoxicity and apoptosis and inhibition of cyclooxigenase-2 gene expression by eugenolrelated compounds. Anticancer Res. 2005;25:3263-3270.
59. Bryant CS, Kumar S, Chamala S, et al. Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells. Mol Cancer. 2010;9:47.
60. Satoh H, Nishikawa K, Suzuki K, et al. Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent. Res Commun Mol Pathol Pharmacol. 2003;113-114:149-158. (Pubitemid 40179779)
61. Tanos V, Brzezinski A, Drize O, Strauss N, Peretz T. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol. 2002;102:188-194. (Pubitemid 34272728)
62. Chen J, Halls SC, Alfaro JF, Zhou Z, Hu M. Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes. Pharm Res. 2004;21:2095-2104. (Pubitemid 40941231)
63. Hwang JT, Ha J, Park OJ. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemoresistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun. 2005;332:433-440. (Pubitemid 40731495)
64. Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395-419. (Pubitemid 28183370)
65. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-1326. (Pubitemid 28406819)
66. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synlhase/cyclooxygenasc homologue. J Biol Chem. 1991;266:12866-12872.
67. Elliott MJ, Stribinskiene L, Lock RB. Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2′-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin.Cancer Chemother Pharmacol. 1998;41:457-463. (Pubitemid 28140709)
68. Haldar S. Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res.1996;56:1253-1255. (Pubitemid 26080965)
69. Cheung KL, Khor TO, Kong AN. Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation.Pharm Res. 2009;26:224-231.
70. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet.1997;349:1137-1141. (Pubitemid 27168548)
71. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med. 1998;4:232-234. (Pubitemid 28137379)
72. Piché A, Grim J, Rancourt C, Gómez-Navarro J, Reed JC, Curiel DT. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 1998;58:2134-2140. (Pubitemid 28232899)
73. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677-681. (Pubitemid 40825512)
74. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2: a molecular target for chemoprevention and treatment. Trends Pharmacol Sci. 2003;24:96-102. (Pubitemid 36135884)
75. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol. 2000;76:320-325.
76. Banerjee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7,12-dimethyl-benz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-κB, cyclooxygenase-2 and matrix metalloproteinase-9. Cancer Res. 2002;62:4945-4954. (Pubitemid 34984418)
77. Iñiguez MA, Rodríguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target for angiogenesis. Trends Mol Med. 2003;9:73-78.
78. Hooshmand S, Soung do Y, Lucas EA, Madihally SV, Levenson CW, Arjmandi BH. Genistein reduces the production of proinflammatory molecules in human chondrocytes. J Nutr Biochem. 2007;18:609-614. (Pubitemid 47212711)
79. Lev-Ari S, Strier L, Kazanov D, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res. 2005;11:6738-6744. (Pubitemid 41339017)
80. Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. Polymorphism of the interleukin-1β gene influences survival in pancreatic cancer. Br J Cancer. 2000;83:1443-1447.
81. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124:1193-1201. (Pubitemid 36531795)
82. Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst. 2002;94:1680-1687. (Pubitemid 35446836)
83. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095-2147. (Pubitemid 26086851)
84. Karin M, Greten FR. NF-B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-759. (Pubitemid 41400849)
85. Estrov Z, Shishodia S, Faderl S, et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003;102:987-995. (Pubitemid 36917794)
86. Moon Y, Glasgow WC, Eling TE. Curcumin suppresses interleukin 1β-mediated microsomal prostaglandin E synthase 1 by altering early growth response gene 1 and other signaling pathways. J Pharmacol Exp Ther. 2005;315: 788-795. (Pubitemid 41500745)
87. Shibata A, Nakagawa K, Yamanoi H, et al. Sulforaphane suppresses ultraviolet B-induced inflammation in HaCaT keratinocytes and HR-1 hairless mice. J Nutr Biochem. 2010;21:702-709.